Roche Bispecific T-Cell Engager Improves Survival in Lymphoma, Teeing up Label Expansion | BioSpace

Published: Apr 15, 2024 By Nick Paul Taylor

Roche_iStock, JHVEPhoto

Pictured: Roche Diagnostics building in California/iStock, JHVEPhoto

Roche‘s Genentech subsidiary on Monday announced that its bispecific T-cell engager Columvi (glofitamab) improved survival in a Phase III lymphoma trial, with the company planning to seek a full, expanded label in a potential challenge to AbbVie and Genmab’s Epkinly (epcoritamab). 

Columvi targets CD3 on T cells and CD20 on B cells, which are malignant in some blood cancers. The bispecific mechanism is designed to put T cells in a position to kill cancerous B cells. Roche received accelerated FDA approval in June 2023 and kept collecting Phase III data to confirm the effects of the therapy.

Roche designed the Phase III trial to compare the effects of Columvi and Rituxan (rituximab) in 270 patients with diffuse large B-cell lymphoma…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks